J C Stevenson|M I Whitehead

Showing results (1-10 of 208) with videos related to

Pageof 21

Sort By:

Lancet (London, England)|February 10, 1990

Transdermal administration of oestrogen/progestagen hormone replacement therapyM I Whitehead, D Fraser, L Schenkel, et al.

Drugs|January 1, 1994

Hormone replacement therapy and the cardiovascular system. Nonlipid effectsJ C Stevenson, D Crook, I F Godsland, et al.

International Journal of Fertility and Menopausal Studies|January 1, 1993

Oral versus transdermal hormone replacement therapyJ C Stevenson, D Crook, I F Godsland, et al.

Lancet (London, England)|October 13, 1979

A physiological role for calcitonin: protection of the maternal skeletonJ C Stevenson, C J Hillyard, I MacIntyre, et al.

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1996

Role of oral pamidronate in preventing bone loss in postmenopausal womenB Lees, S W Garland, C Walton, et al.

British Medical Journal (Clinical Research Ed.)|November 22, 1986

Increased concentration of circulating calcitonin gene related peptide during normal human pregnancyJ C Stevenson, D W Macdonald, R C Warren, et al.

Acta Obstetricia Et Gynecologica Scandinavica. Supplement|January 1, 1981

Effects in postmenopausal women of natural and synthetic estrogens on calcitonin and calcium-regulating hormone secretion. Relevance to postmenopausal osteoporosisM I Whitehead, G Lane, P T Townsend, et al.

Obstetrics and Gynecology|January 1, 1994

Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteinsM S Marsh, D Crook, S I Whitcroft, et al.

Obstetrics and Gynecology|August 1, 1994

Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrationsS I Whitcroft, D Crook, M S Marsh, et al.

Lancet (London, England)|April 23, 1988

Calcitonin for prevention of postmenopausal bone lossI MacIntyre, J C Stevenson, M I Whitehead, et al.

Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:

Pageof 21

Lancet (London, England)|February 10, 1990

Transdermal administration of oestrogen/progestagen hormone replacement therapyM I Whitehead, D Fraser, L Schenkel, et al.

Drugs|January 1, 1994

Hormone replacement therapy and the cardiovascular system. Nonlipid effectsJ C Stevenson, D Crook, I F Godsland, et al.

International Journal of Fertility and Menopausal Studies|January 1, 1993

Oral versus transdermal hormone replacement therapyJ C Stevenson, D Crook, I F Godsland, et al.

Lancet (London, England)|October 13, 1979

A physiological role for calcitonin: protection of the maternal skeletonJ C Stevenson, C J Hillyard, I MacIntyre, et al.

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 1, 1996

Role of oral pamidronate in preventing bone loss in postmenopausal womenB Lees, S W Garland, C Walton, et al.

British Medical Journal (Clinical Research Ed.)|November 22, 1986

Increased concentration of circulating calcitonin gene related peptide during normal human pregnancyJ C Stevenson, D W Macdonald, R C Warren, et al.

Acta Obstetricia Et Gynecologica Scandinavica. Supplement|January 1, 1981

Obstetrics and Gynecology|January 1, 1994

Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteinsM S Marsh, D Crook, S I Whitcroft, et al.

Obstetrics and Gynecology|August 1, 1994

Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrationsS I Whitcroft, D Crook, M S Marsh, et al.

Lancet (London, England)|April 23, 1988

Calcitonin for prevention of postmenopausal bone lossI MacIntyre, J C Stevenson, M I Whitehead, et al.

Pageof 21